RFA-CA-22-025: SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $2.0 million to small businesses. Applications closed on August 5, 2022.
From the official notice on Grants.gov, last changed April 5, 2022. Checked November 7, 2026.
- Award ceiling$2.0 million
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR44
- Clinical trialsOptional
- Funded byNCI
- Median yearly award$1.7 million
- Typical project length7 years
- R44, Small Business Innovation Research (SBIR) Phase II. Full research and development of an SBIR project after Phase I (or both phases at once, called Fast Track). Other open R44 notices.
Projects funded under RFA-CA-22-025 were run by National Cancer Institute (NCI, 7 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-22-025 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-CA-24-022 | April 23, 2024 | Closed August 21, 2024 | Closed |
| RFA-CA-23-034 | April 21, 2023 | Closed August 21, 2023 | Closed |
| RFA-CA-21-036 | March 25, 2021 | Closed August 6, 2021 | Closed |
Key dates
| Posted | April 5, 2022 |
|---|---|
| Deadline | August 5, 2022 |
| Archived by Grants.gov | September 10, 2022 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See Funding Opportunity Announcement for full eligibility details.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $1.7 million; it allows up to $2.0 million per award.
- Most of the money in the 2 programs behind this notice (58% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this FOA is to facilitate the transition of SBIR or STTR Phase II projects to the commercialization stage. This FOA is expected to promote partnerships between Federally-funded SBIR or STTR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital-intensive steps that are required to commercialize new products and services. Applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the Phase IIB Bridge Award project period. It is expected that the level of this independent third-party funding will be equal to or greater than the NCI funds being requested throughout the Phase IIB Bridge Award project period. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as appropriate but are not required.
Funded under RFA-CA-22-025 so far
NIH funded 7 projects under RFA-CA-22-025 in fiscal 2023 to 2025, at 7 institutions. The median yearly award was $1.7 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | Twinstrand Biosciences, Inc. | 2025 | $2.0 million |
| Commercial Readiness for Direct-to-Digital Pathology | Applikate Technologies, Inc. | 2025 | $1.6 million |
| Commercializing CivaSheet for Pancreatic Cancer Patients | Civatech Oncology, Inc. | 2025 | $1.0 million |
| Developing a kit-based research use only (RUO) translocation assay for deployment as a lab developed test (LDT) toward changing outcomes for patients with driver-negative tumors | Arima Genomics, Inc. | 2024 | $1.9 million |
| Manganese Based MRI Contrast Agent | Reveal Pharma | 2024 | $2.0 million |
| One-click Automated 3D Treatment Planning for Radiopharmaceutical Therapy | Voximetry, Inc. | 2024 | $2.0 million |
| Image-guided Surgical Detection of Metastatic Disease to the Peritoneum | Onconano Medicine, Inc. | 2023 | $1 |
Who has won Cancer Treatment Research grants before
From fiscal 2021 to 2025, Cancer Treatment Research (93.395) awarded $5.6 billion across 3,622 grant awards, an average of $1.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 144 | $188 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 68 | $185 million |
| Icahn School of Medicine at Mount Sinai | New York | 35 | $179 million |
| Public Health Institute | California | 4 | $168 million |
| Fred Hutchinson Cancer Center | Washington | 57 | $156 million |
Who has won Cancer Detection and Diagnosis Research grants before
From fiscal 2021 to 2025, Cancer Detection and Diagnosis Research (93.394) awarded $2.7 billion across 1,944 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 56 | $114 million |
| Fred Hutchinson Cancer Center | Washington | 37 | $96.7 million |
| The Leland Stanford Junior University | California | 62 | $89.1 million |
| Sloan-Kettering Institute for Cancer Research | New York | 52 | $88.7 million |
| The Johns Hopkins University | Maryland | 63 | $86.5 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-22-025 still open?
No. It closed on August 5, 2022.
Who can apply for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)?
Closed August 5, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $2.0 million each.
Who has been funded under RFA-CA-22-025?
NIH RePORTER lists 7 projects funded under RFA-CA-22-025 in fiscal 2023 to 2025, at 7 institutions. The most were at Twinstrand Biosciences, Inc., Applikate Technologies, Inc., Civatech Oncology, Inc.
Who has won Cancer Detection and Diagnosis Research grants before?
The largest recipients over five fiscal years were The Regents of the University of California, San Francisco, Fred Hutchinson Cancer Center, The Leland Stanford Junior University. The program made 1,944 awards worth $2.7 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)